Potential oncology therapy guidance by patient-derived tumor cells (PDC)

A compilation of 462 patient-derived tumor cell (PDC) lines points to their potential use in clinical setting.

Standard oncology therapy is based on a procedures common for all patients, in some cases divided to groups of different, single molecular or diagnostic features. This approach may be changed by modern precision medicine techniques, which adjust therapy to a specific patient. One of the proposed methods makes use of living cancer cells.

Cancer cells can be grafted into mice models (PDX – patient-derived xenografts) or cultured in vitro (PDC – patient-derived cells). Investigation of PDC suggests that their time of derivation and amount of data is more viable in precision medicine approach.

After two-three weeks of derivation, PDC can be used to measure response to many drugs and doses simultaneously. In the study, researchers have assessed primary cancer response to 60 various anti-cancer compounds. Further statistical analysis provided detailed individual characteristic of drug sensitivity and resistance. Patient-derived cell lines guide identification of drugs suitable for specific therapeutic procedures, as PI3K inhibitors for gastric cancer, anti-NRG1 for EGFR-resistant tumors, and many others.

More: “Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy”, J. Lee et al., 2018, doi:10.1038/s41588-018-0209-6.